S1pr2 antagonist, JTE013, has been reported to exert beneficial effects in various disease models: pharmacological inhibition of S1pr2 retarded the development of spontaneous hemorrhagic transformation and promoted cerebrovascular integrity in an experimental stroke animal model; JTE013 alleviated inflammatory bone loss disease in mice; blockade of S1pr2 attenuated allergic asthma in a mouse model; S1pr2 inhibitor reduced portal vein pressure and protect against liver injury in a rat model 24, 31-33. Here, S1PR2 is linked to stroke disorder.